Viatris (VTRS, Financials) shares fell 3.6% on Friday after the firm said that its late-stage clinical study of the blepharitis medication MR-139 did not fulfill its main goal. The study examined pimecrolimus 0.3% ophthalmic ointment on 477 individuals for 12 weeks. Its goal was to get rid of eyelid debris, which is a major sign of blepharitis, but it didn't completely go away after six weeks of therapy.
Viatris is currently thinking about its choices. The company's Chief R&D Officer said that the team might change its plans for future MR-139 trials. Viatris is still hopeful, even though this setback. Its pipeline still contains potential therapies like Tyrvaya and RYZUMVI, and it recently published good findings from two other Phase 3 studies, LYNX-2 and VEGA-3, which were looking at keratorefractive problems and presbyopia, respectively.
The company's long-term plan is still to work on treatments for anterior segment disorders in ophthalmology, and management have said they will keep working on these unmet requirements.
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target
The study did not meet its main endpoint of clearing eyelid debris in blepharitis patients.
3 days ago
Summary
- Viatris is reassessing its next steps but remains committed to other late-stage drug programs.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers